Scrip Awards Finalists · seeks to reward the growing pharmaceutical industry founded in areas...
1
Best Company in an Emerging Market Community Partnership of the Year Award (Sponsored by Medidata) Scrip Awards Finalists Scrip’s Best Company in an Emerging Market Award seeks to reward the growing pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan. To find out more about attending the Scrip Awards, visit www.scripawards.com This Scrip Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community. Beximco Pharma continues to build its presence in emerging and developed markets. It launched nine new products in its domestic market and began exporting to Canada, Uzbekistan and Zambia. It also acquired a majority stake in Nuvista Pharma, a leading Bangladeshi pharma company specialising in hormones and steroid drugs. Beximco Pharmaceuticals Biocon established its credibility as a global biologics player by successfully navigating the complexities in the research, development, manufacturing and regulatory approvals of these advanced therapies. It was the first company to get a biosimilar trastuzumab approved in the US and was among the first to receive insulin glargine approval in Europe. Biocon CinnaGen plays a leading role in improving healthcare systems, not only in its home country of Iran but also in the MENA region. The group has launched 13 biosimilar medicines, using cutting-edge technology, into the Iran market. Over half a million patients used CinnaGen medicines last year, a growth of 18%. CinnaGen Pharmaceutical Group Chi-Med has emerged as a leading, fully-integrated, China-based healthcare group, positioned as a risk-balanced globally focused biopharma company, active in researching, developing, manufacturing and commercializing pharmaceuticals and health-related consumer products such as fruquintinib. In late 2017, Chi-Med also completed a Nasdaq follow-on offering, raising net proceeds of $292.7m. Hutchison China MediTech (Chi-Med) With its regional emerging markets hub in Singapore – and a global network across the Asia-Pacific, Latin America, the Middle East and Africa – Mundipharma’s medicines now reach patients in 128 countries in six continents. In tandem with its patient-centric approach, Mundipharma’s entrepreneurial spirit has enabled the company to grow its portfolio to over 38 medicines. Mundipharma Singapore Working with the proceeds of its June 2017 IPO, and a 230% stock price market growth achieved since, China’s WuXi Biologics has started constructing three new drug development and manufacturing sites, including one in Ireland. It also passed a significant milestone by being approved by the US FDA to manufacture a commercial biologic drug. WuXi Biologics AstraZeneca has expanded its business mentoring initiatives in Cambridge: to support Accelerate@Babraham, a new bio-incubator and life science accelerator at the Babraham Research Campus; a collaboration with Lucy Cavendish College to support advancing women in science and business leadership; plus it has launched its AstraZeneca Start-Up Science competition to support life sciences start-ups. AstraZeneca’s Mentoring Team This tripartite effort aims to support, for free, community nutrition and health research intended to test, discover, inform and guide policies that can lift the health burden of micronutrient deficiencies from women, infants and children in impoverished regions of rural Bangladesh and South Asia. Beximco Pharma with DSM Nutritional Products and Sight & Life Global Nutrition Research Institute to improve nutrition in rural Bangladesh For the first time since its inception, Race for 7 expanded beyond Bangalore to Mumbai and Washington. The event drew close to 6,000 participants across three cities, including rare disease patients, their caregivers, healthcare professionals and the general public, all united by a common cause – to commemorate World Rare Disease Day. IQVIA India’s Race for 7 with the Organization for Rare Diseases India Open Pharma is a partnership of the pharmaceutical industry, publishers, patients, academics and regulators, which aims to identify and make the changes needed to improve transparency and accessibility of medical research. It has led to meaningful policy and behavioural changes, including the launch of the first pharmaceutical company open access policy. Oxford PharmaGenesis’ Open Pharma 2018 www.scripawards.com Sponsored by Social Media Sponsor Headline Sponsor JN1498 Scrip Awards 2018 Preview Ad 12-10.indd 1 2018/10/08 15:54
Transcript of Scrip Awards Finalists · seeks to reward the growing pharmaceutical industry founded in areas...
Best Company in an Emerging Market Community Partnership of the Year Award (Sponsored by Medidata)
Scrip AwardsFinalists
Scrip’s Best Company in an Emerging Market Award seeks to reward the growing pharmaceutical industry founded in areas beyond its traditional geographic borders of North America, Western Europe and Japan.
To find out more about attending the Scrip Awards, visit www.scripawards.com
This Scrip Award is designed to acknowledge the numerous ways in which pharma and biotech companies give back to the wider community.
Beximco Pharma continues to build its presence in emerging and developed markets. It launched nine new products in its domestic market and began exporting to Canada, Uzbekistan and Zambia. It also acquired a majority stake in Nuvista Pharma, a leading Bangladeshi pharma company specialising in hormones and steroid drugs.
Beximco Pharmaceuticals
Biocon established its credibility as a global biologics player by successfully navigating the complexities in the research, development, manufacturing and regulatory approvals of these advanced therapies. It was the first company to get a biosimilar trastuzumab approved in the US and was among the first to receive insulin glargine approval in Europe.
Biocon
CinnaGen plays a leading role in improving healthcare systems, not only in its home country of Iran but also in the MENA region. The group has launched 13 biosimilar medicines, using cutting-edge technology, into the Iran market. Over half a million patients used CinnaGen medicines last year, a growth of 18%.
CinnaGen Pharmaceutical Group
Chi-Med has emerged as a leading, fully-integrated, China-based healthcare group, positioned as a risk-balanced globally focused biopharma company, active in researching, developing, manufacturing and commercializing pharmaceuticals and health-related consumer products such as fruquintinib. In late 2017, Chi-Med also completed a Nasdaq follow-on offering, raising net proceeds of $292.7m.
Hutchison China MediTech (Chi-Med)
With its regional emerging markets hub in Singapore – and a global network across the Asia-Pacific, Latin America, the Middle East and Africa – Mundipharma’s medicines now reach patients in 128 countries in six continents. In tandem with its patient-centric approach, Mundipharma’s entrepreneurial spirit has enabled the company to grow its portfolio to over 38 medicines.
Mundipharma Singapore
Working with the proceeds of its June 2017 IPO, and a 230% stock price market growth achieved since, China’s WuXi Biologics has started constructing three new drug development and manufacturing sites, including one in Ireland. It also passed a significant milestone by being approved by the US FDA to manufacture a commercial biologic drug.
WuXi Biologics
AstraZeneca has expanded its business mentoring initiatives in Cambridge: to support Accelerate@Babraham, a new bio-incubator and life science accelerator at the Babraham Research Campus; a collaboration with Lucy Cavendish College to support advancing women in science and business leadership; plus it has launched its AstraZeneca Start-Up Science competition to support life sciences start-ups.
AstraZeneca’s Mentoring Team
This tripartite effort aims to support, for free, community nutrition and health research intended to test, discover, inform and guide policies that can lift the health burden of micronutrient deficiencies from women, infants and children in impoverished regions of rural Bangladesh and South Asia.
Beximco Pharma with DSM Nutritional Products and Sight & Life Global Nutrition Research Institute to improve nutrition in rural Bangladesh
For the first time since its inception, Race for 7 expanded beyond Bangalore to Mumbai and Washington. The event drew close to 6,000 participants across three cities, including rare disease patients, their caregivers, healthcare professionals and the general public, all united by a common cause – to commemorate World Rare Disease Day.
IQVIA India’s Race for 7 with the Organization for Rare Diseases India
Open Pharma is a partnership of the pharmaceutical industry, publishers, patients, academics and regulators, which aims to identify and make the changes needed to improve transparency and accessibility of medical research. It has led to meaningful policy and behavioural changes, including the launch of the first pharmaceutical company open access policy.
Oxford PharmaGenesis’ Open Pharma
2018 www.scripawards.com
Sponsored by Social Media SponsorHeadline Sponsor
JN1498 Scrip Awards 2018 Preview Ad 12-10.indd 1 2018/10/08 15:54
